Allergic response to environmental allergens is a common health problem. It is still unclear how allergens trigger the innate immune system, which in turn induces long-lasting type 2 adaptive responses. Epithelial cells, as the fi rst cell type encountering allergens, have been shown to initiate tissue infl ammatory responses by producing various cytokines and chemokines, which may create a permissive environment for the recruitment of infl ammatory cells and amplifi cation of allergic responses. CD4 + Th cells are essential regulators in chronic allergic diseases. Upon activation, Th cells undergo diff erentiation into functionally distinct eff ector subsets. Th1 cells produce IFN-γ and regulate cellular immunity, whereas Th2 cells produce IL-4, IL-5, and IL-13 and mediate humoral immunity and allergic responses (1, 2) . A novel Th cell subset expressing IL-17 regulates tissue infl ammatory responses (3) . During Th2 cell diff erentiation, in which GATA-3 serves as a master transcription factor (2), IL-4 produced by activated Th cells is essential for driving Th2 cell diff erentiation (1). NFATc1 and JunB have been shown to be important in regulating early IL-4 production and in determining Th2 cell diff erentiation (4) . The terminal diff erentiation of Th cells is determined by the innate immune system and the cytokines it produces. Despite the molecular understanding of the Th2 cell regulatory programs, whether there is a signal induced during the innate response to allergens that augments IL-4 expression by T cells and regulates Th2 cell diff erentiation remains unclear.
IL-25 (also known as IL-17E), a member of the IL-17 family, has been implicated in Th2 cell-mediated immunity (5, 6) . IL-25 shares a receptor, named IL-17RB, with IL-17B, although it binds with much higher affi nity than IL-17B (7). IL-17RB mRNA transcripts are abundantly expressed in the kidney and liver and at lower levels in the testes, brain, small intestine, and other organs (7) . Overexpression of IL-25 or administration of recombinant cytokine strongly induced Th2 cytokine expression and IgE production in vivo and resulted in allergic pathologies (5, 6, 8, 9) . Conversely, mice defi cient in IL-25 exhibited reduced Th2 cytokine production in the draining lymph nodes, resulting in poor resistance to Trichuris infection (10, 11) . The molecular mechanisms whereby IL-25 regulates type 2 immunity are still unclear. A non-B/T cell population was found to be regulated by IL-25 and produce Th2 cytokines in response to Nippostrongylus brasiliensis infection (11) . However, given the broad expression of IL-17RB, additional targets of IL-25 may exist to regulate allergic responses.
In this report, we found that IL-25 mRNA was up-regulated in epithelial cells after allergen stimulation. Chronic overexpression of IL-25 in airway epithelium resulted in asthma symptoms, whereas blockade of IL-25 attenuated allergeninduced lung infl ammation and Th2 cytokine expression. Moreover, we found that IL-25 directly promoted Th2 cell differentiation and GATA-3 expression in an IL-4-and STAT6-dependent manner. IL-25 enhanced NFATc1 and JunB expression to potentiate early IL-4 expression and the expansion and cytokine production of eff ector Th2 cells.
RESULTS AND D I S C U S S I O N Expression of IL-25 by lung epithelial cells initiates allergic responses
In an attempt to defi ne the initial innate mechanism in response to allergens, we treated a mouse lung epithelial cell line, MLE12, with the allergens Aspergillus oryzae and ragweed and characterized gene expression changes by RT-PCR. In addition to several chemokine genes (not depicted), we found that IL-25 mRNA was substantially induced in response to the allergens (Fig. 1 A) . The expression of IL-25 by lung epithelial cells was further confi rmed using a human lung epithelial cell line, A549, and primary type II alveolar epithelial cells isolated from C57BL/6 mice ( Fig. 1 A) . Our data are consistent with a previous observation of upregulation of IL-25 mRNA in lung tissue in response to A. fumigatus infection (5), suggesting that IL-25 induction in lung epithelial cells may play a role in initiating a type II immune response to allergens.
To address the function of IL-25 produced by lung epithelial cells in vivo, we generated transgenic mice that overexpress IL-25 in lung epithelium using the CC10 promoter. Four founder lines were generated, of which two expressed high levels of IL-25 mRNA in the lung tissue and were selected for histological analysis. Transgenic mice exhibited greatly increased levels of IL-25 mRNA expression in their lung tissues and protein in the bronchoalveolar lavage (BAL) fl uid (Fig. S1 , available at http://www.jem.org/cgi/content/ full/jem.20061675/DC1). Compared with littermate controls, IL-25 transgenic mice exhibited epithelial cell hyperplasia at 3 mo of age; after 3 mo of age, we observed goblet cell hyperplasia, epithelial cell hyperplasia, and infi ltration of moderate numbers of eosin-stained enlarged macrophages and considerable numbers of eosinophils in the lung parenchyma (Fig. 1 B) . Similar macrophage infi ltration was found in cc10-IL-17 (12) and cc10-IL-17F (unpublished data) mice, whereas eosinophils were only seen in cc10-IL-25 mice. However, cc10-IL-13 transgenic mice were also found to have lung infi ltration by macrophages and eosinophils (13) . By performing periodic acid Schiff (PAS) staining, mucusproducing cells were found only in IL-25 transgenic mice and not in the control littermates (Fig. 1 B) . In older IL-25 transgenic mice between 7 and 10 mo of age, substantial infi ltration of CD4 + T cells and CD11C + dendritic cells were found around blood vessels (unpublished data). IL-25 overproduction in lung epithelium thus led to allergic infl ammation in the lung.
To further investigate the regulation of allergic responses by IL-25, we examined cytokine and chemokine expression profi les in lung tissues of IL-25 transgenic mice and their littermate controls. The expression of eotaxin1 (Ccl11), eotaxin2 (Ccl24), and MDC (Ccl22), which play crucial roles in the recruitment of eosinophil and Th2 cells, respectively, were detected in IL-25 transgenic mice ( Fig. 1 C) . Interestingly, mRNA for MUC5ac, the protein product of which constitutes a major component of respiratory lining fl uid, was elevated in IL-25 transgenic mice, correlating with mucus hypersecretion in the airways of these mice. To determine whether these chemokines and mucin are direct targets of IL-25, the MLE12 cell line was treated with IL-25, and the resulting gene expression changes were determined. Expression of chemokines relevant to eosinophil (eotaxin1) and Th2 cell (regulated on activation, normal T cell expressed and secreted/CCL5 and MDC) recruitment, as well as MUC5ac, was strongly induced by IL-25 ( Fig. 1 D) . In addition, we also observed up-regulation of TSLP, which was recently established as a key factor in allergic infl ammation (14) . Collectively, these data indicate that IL-25 induced by allergens in epithelial cells can function to initiate allergic responses.
To further examine the role of IL-25 during immune responses to allergens, a panel of rat anti-mouse IL-25 mAbs was generated and screened for its abilities to inhibit the binding of IL-25 to 293 cells transfected with IL-17RB. One clone (35B) was identifi ed as an antagonistic antibody (unpublished data), which was used in an allergen-induced experimental asthma model. C57BL/6 mice were intranasally sensitized with allergens derived from A. oryzae together with chicken OVA protein every other day for a total of six challenges, as previously described (15) . The airway pathology developed in this model was previously found to be dependent on IL-4 (16). Anti-IL-25 antibody or a control rat IgG was intraperitoneally administered at the time of each challenge. 24 h after the last allergen administration, the BAL and lungs were collected. In BAL fl uid, the presence of infl ammatory cells was assessed by diff erential cell counting and BRIEF DEFINITIVE REPORT fl ow cytometry analysis, and the levels of cytokine production were determined by ELISA. Compared with mice treated with a control rat antibody, anti-IL-25 substantially reduced the number of eosinophils, an important indicator of airway infl ammation; the infi ltration of CD4 + T cells was moderately reduced (Fig. 1 E) . Although the production of IFN-γ in BAL was moderately increased and TNF-α was not aff ected, Th2 cytokines (IL-4, IL-5, and IL-13) were all signifi cantly reduced by anti-IL-25 treatment ( Fig. 1 F) , indicating that the IL-25 blockade may attenuate allergic airway infl ammation through the reduction of the Th2 response. However, we observed no change in the goblet cell hyperplasia by anti-IL-25 treatment, suggesting that the remaining cytokines or other factors were suffi cient in this regulation. For example, IL-13 has been previously indicated as an important cytokine with a distinct role from IL-4 in regulating the development of allergic asthma symptoms, including airway hyperesponsiveness, goblet cell hyperplasia, tissue remodeling, and fi brosis (17) . To further investigate the role of IL-25 in regulating T cell function during allergic responses, we restimulated splenocytes from the described experiment ex vivo with OVA protein for 3 d and measured their cytokine production. Similar to the BAL data, antigen-specifi c Th2 responses in cells from anti-IL-25-treated mice were reduced, especially the production of IL-5 and IL-13, whereas no alteration in the levels of IFN-γ and TNF-α was observed (unpublished data). Our data suggest that IL-25 regulates Th2 cell function during allergic responses. This result is consistent with recent studies on the important function of IL-25 in mediating antiparasitic immune responses (10, 11) and in airway infl ammation (18) , suggesting that allergens and large parasites may use a common pathway in activation of Th2 responses. previously reported (19) (20) (21) , suggesting a possible function of IL-25 on T cells. To further investigate this idea, we fi rst examined expression of the IL-25 receptor IL-17RB on diff erent mouse Th cell populations. IL-17RB expression was detected on freshly isolated naive CD4 + T cells. After in vitro diff erentiation, Th2 but not Th1 cells maintained this expression (Fig. 2 A) . Moreover, IL-17RB expression was not detected in in vitro-generated IL-17-producing Th cells (unpublished data), indicating that IL-17RB expression is restricted to Th2 cells among three eff ector Th cell subsets.
IL-25 promotes Th2 cell differentiation in vitro
The selective expression of IL-17RB suggests that IL-25 may play a role in regulating Th2 cell diff erentiation. To assess this, CD44 lo CD62L hi naive CD4 + T cells from C57BL/6 mice were cultured with anti-CD3, anti-CD28, and IL-2 in the presence or absence of IL-25. 4 d later, diff erentiated cells were restimulated with anti-CD3, and cytokine expression was examined by ELISA. Although T cells activated in the absence of IL-25 predominately diff erentiated into IFN-γ-producing Th1 cells, IL-25 treatment led to greatly increased levels of IL-4, IL-5, and IL-13 expression and moderately reduced amounts of IFN-γ expression by eff ector T cells (Fig. 2 B) . By intracellular cytokine staining, we found that IL-25 treatment resulted in substantially increased numbers of IL-4-producing Th2 cells, which was more pronounced when IFN-γ was neutralized (Fig. 2 C) . The eff ect of IL-25 on Th2 cytokine expression was dose dependent and inhibited by anti-IL-25 antibody (Fig. 2 D) . Our data indicate a novel function of IL-25 in directly promoting Th2 cell diff erentiation. (Fig. 3 A) . The induction of IL-4 and other Th2 cytokines was increasingly pronounced by day 3 of activation, suggesting that IL-25 may regulate early Th2 cytokine gene expression. To determine whether IL-25-mediated Th2 cell diff erentiation depends on early IL-4 
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production by T cells, we performed the Th cell diff erentiation experiment in the presence of neutralizing anti-IL-4 antibody. Anti-IL-4 completely abolished IL-4 and IL-5 production and moderately inhibited IL-13 induction, as determined by ELISA and real-time RT-PCR analysis on day 4 after activation (Fig. 3, B and C) . Similarly, although IL-25 promoted Th2 cell diff erentiation in wild-type T cells, IL-25 was not able to induce IL-4 and IL-5 production by IL-4-defi cient cells (Fig. 3 D) , though residual expression of IL-13 was still detectable. Thus, IL-25-mediated Th2 cell diff erentiation is dependent on IL-4.
STAT proteins are selectively required in cytokinemediated Th cell lineage diff erentiation. Because IL-25 promotion of Th2 cell diff erentiation is dependent on IL-4, we tested whether STAT6 is involved. Naive CD4 + T cells were activated with anti-CD3 and anti-CD28 with or without IL-25 or with IL-25 and anti-IL-4 neutralizing antibody for 2 d and subjected them to a Western blot analysis of STAT3, STAT5, and STAT6 phosphorylation. IL-6, IL-2, and IL-4 were included as the positive controls for STAT3, STAT5, and STAT6 phosphorylation, respectively. IL-25 treatment, although not aff ecting STAT3 and STAT5 phosphorylation, enhanced that of STAT6 (Fig. 4 A) . Because STAT6 phosphorylation was completely abolished by an anti-IL-4 antibody (Fig. 4 A) , STAT6 is likely activated by IL-4. To further address the possibility that IL-25 directly phoshorylates STAT6 or enhances IL-4 signaling, naive Th cells isolated from IL-4-defi cient mice were activated with anti-CD3 and CD28 (Fig. 4 B) . These data support the conclusion that the regulation of Th2 cell diff erentiation by IL-25 is dependent on the IL-4-STAT6 signaling pathway.
IL-25 induces early IL-4 expression through JunB and NFATc1
Early IL-4 production, through STAT6, plays an important role in regulating the expression of GATA-3, a master regulator of Th2 cell development. To examine the molecular mechanism whereby IL-25 regulates Th2 cell diff erentiation, we assessed the expression of GATA-3. Naive T cells were activated in the absence or presence of IL-25. At day 2 after activation, T cells were analyzed for the mRNA expression of GATA-3 and T-bet by real-time PCR analysis. Although no change in the T-bet expression level was detected, considerable up-regulation of GATA-3 mRNA was observed upon IL-25 stimulation (Fig. 5 A) . Similarly, GATA-3 protein expression was enhanced by IL-25 at this time point (Fig. 5 A) . GATA-3 mRNA and protein expression was inhibited by anti-IL-4 antibody (Fig. 5 A) . These results indicate a function of IL-25 in GATA-3 regulation, which is dependent on IL-4.
To understand the mechanisms whereby IL-25 regulates early IL-4 production, we also measured the expression of additional transcription regulators. NFATc1 and JunB are important in controlling early IL-4 expression during Th2 cell diff erentiation (4). Interestingly, we found that the protein expression of NFATc1 and JunB was substantially increased in the presence of IL-25, and this up-regulation could not be completely blocked by anti-IL-4 (Fig. 5 A) . Our results suggest that IL-25 may regulate early IL-4 expression directly through potentiating the induction of NFATc1 and JunB, which leads to IL-4-dependent up-regulation of GATA-3 expression.
Regulation of effector Th2 cells by IL-25
Because IL17RB expression is restricted to Th2 cells, we next examined whether IL-25 plays an additional role in polarized Th2 cells. Naive T cells isolated from OT-II TCR transgenic mice were diff erentiated into Th1 or Th2 cell lineages. After 5 d of polarization, Th1 and Th2 cells were restimulated with anti-CD3 in the absence or presence of IL-25. As shown by intracellular cytokine analysis of IL-4 and 
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IFN-γ expression, IL-25 treatment resulted in an increased number of IL-4-expressing Th2 cells while having no eff ect on IFN-γ-secreting Th1 cells (Fig. 5 B) . Consistently, IL-25 also enhanced the production of IL-4 and IL-5 in Th2 cells generated from naive T cells isolated from C57BL/6 mice but not IFN-γ and TNF-α production in Th1 cells (Fig. 5 C) . Thus, IL-25 functions not only by potentiating early IL-4 production to promote Th2 cell diff erentiation but also by enhancing the expansion and cytokine production of eff ector Th2 cells.
In summary, we found that IL-25, up-regulated in lung epithelial cells exposed to allergens, functions to regulate proallergic responses in vivo. More importantly, we discovered a direct function of IL-25 on Th cells in promoting Th2 cell diff erentiation and enhancing Th2 cytokine production in polarized Th2 cells. We identifi ed NFATc1 and JunB as the transcription factors directly regulated by IL-25 to increase early IL-4 production, which results in enhanced GATA-3 expression and Th2 cell diff erentiation. This action of IL-25 resembles those of inducible T cell co-stimulator (22) and OX40 (23) . As a result of polarized diff erentiation, Th2 cells selectively express IL-17RB and respond to IL-25 for their expansion and cytokine production. All of these data support an important function of IL-25 in type II immunity; IL-25 may serve as a therapeutic target for diseases such as allergic asthma. In addition, recent fi ndings by Owyang et al. using a gut infection model indicated that IL-25 is required for limiting type 1 infl ammation (10) . The mechanisms we identifi ed in this report whereby IL-25 regulates type II responses may apply to nonallergic systems and may be benefi cial in protecting hosts from uncontrolled immune-mediated pathology.
MATERIALS AND METHODS
Generation of IL-25 recombinant protein and anti-IL-25 mAbs.
Recombinant mouse IL-25-Ig protein was prepared as we previously reported (24) . Anti-IL-25 mAbs were generated as previously described (25) .
Generation and analysis of IL-25 transgenic mice. Full-length cDNA encoding mouse IL-25 was cloned into the cc10 promoter construct (a gift from J. Elias, Yale University, New Haven, CT), as we previously did for the IL-17 transgenic mouse (12) . The IL-25 transgene construct was microinjected into C57BL/6 mice at the Transgenic Mouse Facility at the University of Washington. Four IL-25 transgenic founders were obtained and bred with B6 mice. Two transgenic lines expressing high IL-25 mRNA levels were further characterized. The level of IL-25 expression was determined by RT-PCR and ELISA using an ELISA kit (R&D Systems). For histological analysis of IL-25 transgenic mice, 6-40-wk-old IL-25 transgenic mice or littermate controls were killed, and individual lungs were fi xed in 10% buff er formalin or frozen. Hematoxylin and eosin (H&E), Giemsa, and PAS staining were performed by Histology Consultation Services, Inc.
Lung epithelial cell culture. Mouse lung epithelial (MLE12) and human lung epithelial (A549) cell lines were obtained from American Type Culture Collection. Primary lung epithelial cells were isolated from C57BL/6 mice, as previously described (26) , after depletion with anti-CD32/CD16 and anti-CD45 antibodies (Miltenyi Biotec). Cells were treated with 200 ng/ml A. oryzae protease or ragweed. After 6 h of stimulation, cells were collected and lysed, and mRNA was extracted by using TRIzol reagent (Invitrogen).
Induction and analysis of an asthma model. C57BL/6 mice were induced with airway infl ammation by A. oryzae for six total challenges, as previously described (15) . Anti-IL-25 or 100 μg of a control rat Ig was given intraperitoneally at the time of challenge. 24 h after the last challenge, mice were killed for analysis of BAL fl uid. BAL cells were collected and further subjected to diff erential cell counts and fl ow cytometry analysis by staining with mAb to CCR3 for eosinophils and CD4 (BD Biosciences). BAL fl uid was measured for cytokines by ELISA. All animal studies were approved by the MD Anderson Cancer Center Institutional Animal Care and Use Committee.
Th cell diff erentiation. Lymph nodes and spleens of various mice were FACS-sorted based on the CD4 + CD62L hi CD44 lo surface phenotypes (96-99% purity) and stimulated with 2 μg/ml of plate-bound anti-CD3 plus 5 μg/ml of soluble anti-CD28 and 50 U/ml of human IL-2 in the presence of 2 μg/ml of human Ig or IL-25Ig or 500 ng/ml of human IL-25 (R&D Systems). After 4 d of restimulation, cells were washed and restimulated with 2 μg/ml of plate-bound anti-CD3 for 24 h, and culture supernatants were collected and analyzed for cytokines by ELISA. Naive T cells from OT-II mice purifi ed by FACS sorting were diff erentiated into Th1 or Th2 cells, as we previously reported (27) . After 5 d of stimulation, Th1 and Th2 cells were restimulated with 0.5 μg/ml anti-CD3 with or without IL-25 for an additional 3 d. For intracellular cytokine analysis, cells were restimulated with 500 ng/ml ionomycin and 50 ng/ml PMA in the presence of GolgiStop (BD Biosciences) for 5 h. Cells were permeabilized with a Cytofi x/Cytoperm kit (BD Biosciences) and analyzed for the expression of IFN-γ, IL-4, and IL-5.
RT-PCR analysis. Total RNA extracted using TRIzol reagent was used to generate cDNA using oligo-dT, random hexamers, and SuperScript RT II (Invitrogen). For quantitation of cytokine and transcription factor gene expression, cDNA samples were amplifi ed in iQ SYBR Green Supermix (BioRad Laboratories). The primer pairs used for RT-PCR are shown in Table S1 (available at http://www.jem.org/cgi/content/full/jem.20061675/DC1).
Immunoblot analysis. Cell lysates prepared as previously reported (22) were subjected to Western blot analysis with anti-phospho-STAT6 (Tyr641), antiphospho-STAT5 (Tyr694), anti-phospho-STAT3 (Tyr705), STAT3, STAT5a, and STAT6 antibodies (provided by K. Arima and E. Esashi, University of Texas MD Anderson Cancer Center, Houston, TX) and antiactin (SigmaAldrich), anti-GATA-3, and anti-JunB (Santa Cruz Biotechnology, Inc.) antibodies. The signal was detected with ECL reagent (Pierce Chemical Co.).
Statistical analysis.
Data are presented as mean values + SD. Data were analyzed using the Student's t test (n = 2 groups). P < 0.05 was considered signifi cant.
Online supplemental material. Fig. S1 shows an analysis of IL-25 expression by real-time PCR and ELISA in transgenic mice and control littermates. Table S1 provides the primer pairs used for RT-PCR analysis. Online supplemental material is available at http://www.jem.org/cgi/content/full/jem.20061675/DC1.
